Literature DB >> 16531543

First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.

M Salazar, A Barata, S André, J Venâncio, I Francisco, M Cravo, C Nobre-Leitão.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16531543      PMCID： PMC1856177          DOI： 10.1136/gut.2005.086744

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  6 in total

1.  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authors:  B P Rubin; S Singer; C Tsao; A Duensing; M L Lux; R Ruiz; M K Hibbard; C J Chen; S Xiao; D A Tuveson; G D Demetri; C D Fletcher; J A Fletcher
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

Review 2.  Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

Authors:  J-Y Blay; S Bonvalot; P Casali; H Choi; M Debiec-Richter; A P Dei Tos; J-F Emile; A Gronchi; P C W Hogendoorn; H Joensuu; A Le Cesne; J McClure; J Mac Clure; J Maurel; N Nupponen; I Ray-Coquard; P Reichardt; R Sciot; S Stroobants; M van Glabbeke; A van Oosterom; G D Demetri
Journal:  Ann Oncol       Date:  2005-04       Impact factor: 32.976

Review 3.  Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.

Authors:  I Pidhorecky; R T Cheney; W G Kraybill; J F Gibbs
Journal:  Ann Surg Oncol       Date:  2000-10       Impact factor: 5.344

4.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

5.  Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

Authors:  Seiichi Hirota; Akiko Ohashi; Toshirou Nishida; Koji Isozaki; Kazuo Kinoshita; Yasuhisa Shinomura; Yukihiko Kitamura
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

6.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245
  6 in total
  9 in total

1.  Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.

Authors:  Carla Rameri Alexandre Silva de Azevedo; Tadeu Ferreira Paiva; Benedito Mauro Rossi; Gustavo Cardoso Guimarães; Maria Dirlei Ferreira de Souza Begnami; Thiago Bueno Oliveira; Milton José Barros E Silva; Marcello Ferretti Fanelli; Celso Abdon Lopes de Mello
Journal:  Int J Clin Oncol       Date:  2010-10-05       Impact factor: 3.402

2.  Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.

Authors:  Seiji Suzuki; Koji Sasajima; Masayuki Miyamoto; Hidehiro Watanabe; Tadashi Yokoyama; Hiroshi Maruyama; Takeshi Matsutani; Aimin Liu; Masaru Hosone; Shotaro Maeda; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

3.  Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum.

Authors:  Yoshiya Fujimoto; Takashi Akiyoshi; Tsuyoshi Konishi; Satoshi Nagayama; Yosuke Fukunaga; Masashi Ueno
Journal:  Int J Colorectal Dis       Date:  2013-09-10       Impact factor: 2.571

4.  Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.

Authors:  Takashi Akiyoshi; Masatoshi Oya; Yoshiya Fujimoto; Hiroya Kuroyanagi; Masashi Ueno; Toshiharu Yamaguchi; Shunji Takahashi; Kiyohiko Hatake; Masamichi Katori; Noriko Yamamoto; Tetsuichiro Muto
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

5.  Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors.

Authors:  Silke Cameron; Theodoros Savvoukidis; Thomas Armbrust; Florian Haller; Julia Kitz; László Füzesi; Giuliano Ramadori
Journal:  Med Oncol       Date:  2009-03-18       Impact factor: 3.064

6.  Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor.

Authors:  Ying-Yong Hou; Yang Zhou; Shao-Hua Lu; Wei-Dong Qi; Cheng Xu; Jun Hou; Yun-Shan Tan
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

7.  Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery.

Authors:  Caio Sergio Rizkallah Nahas; Sergio Carlos Nahas; Carlos Frederico Sparapan Marques; Rafael Schmerling; Leonardo Alfonso Bustamante-Lopez; Ulysses Ribeiro; Ivan Cecconello
Journal:  Arq Bras Cir Dig       Date:  2015

Review 8.  Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review.

Authors:  Tingting Wu; Xiaobin Cheng; Wenbin Chen
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 9.  Advances and Challenges on Management of Gastrointestinal Stromal Tumors.

Authors:  Lin Mei; Wei Du; Michael Idowu; Margaret von Mehren; Sosipatros A Boikos
Journal:  Front Oncol       Date:  2018-05-07       Impact factor: 6.244
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.